4-fluoro-N-butylphenylacetamide:: a synthetic phenylacetate derivative that upregulates Bcl-Xs, activates caspase cascade and induces apoptosis in human squamous lung cancer CH27 cells

被引:10
作者
Chan, HC
Kuo, SC
Liu, SC
Liu, CH
Hsu, SL
机构
[1] Taichung Vet Gen Hosp, Dept Educ & Res, Taichung, Taiwan
[2] Taichung Vet Gen Hosp, Dept Med Res, Taichung, Taiwan
[3] China Med Coll, Dept Biochem, Taichung, Taiwan
[4] China Med Coll, Grad Inst Pharmacuet Chem, Taichung, Taiwan
[5] Chung Shan Med Univ, Sch Med, Taichung, Taiwan
关键词
phenylacetate derivative; Bcl-X-s; caspase; apoptosis;
D O I
10.1016/S0304-3835(02)00352-X
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Phenylacetate (PA) and related aromatic fatty acids induce antiproliferation and differentiation of cancer cell; they have potent anti-tumor properties with relatively low toxicity. To search for more potent analogues of PA, PA derivatives have been synthesized. In this study, we investigated the effects of six synthetic PA derivatives on the growth of human lung cancer cells. Results showed that the anti-proliferative effects of these synthetic compounds were strong than those of PA, 4-fluoro-N-butylphenylacetamide (H6) is the most potent compound. 4,6-Diamidino-2-phenylindole (DAPI) staining, in situ TUNEL assay and DNA gel electrophoresis analysis indicated that a marked reduction in the number of CH27 cells with H6 was related to the induction of apoptosis. The apoptosis triggered by H6 was accompanied by up-regulation of Bcl-X-S, accumulation of cytosolic cytochrome c and activation of caspase cascade (caspase-9 and -3). Furthermore, H6 induces proteolytic cleavage of poly (ADP-ribose) polymerase, which followed the appearance of caspase activity and preceded DNA fragmentation. Pretreatment with caspase inhibitors markedly inhibited H6-induced caspase activity and apoptosis. These results suggest that H6 may induce apoptosis through a Bcl-X-S and caspase-dependent mechanism. (C) 2002 Elsevier Science Ireland Ltd. All rights reserved.
引用
收藏
页码:211 / 221
页数:11
相关论文
共 43 条
  • [1] ADAM L, 1995, CANCER RES, V55, P5156
  • [2] The Bcl-2 protein family
    Antonsson, B
    Martinou, JC
    [J]. EXPERIMENTAL CELL RESEARCH, 2000, 256 (01) : 50 - 57
  • [3] BCL-X, A BCL-2-RELATED GENE THAT FUNCTIONS AS A DOMINANT REGULATOR OF APOPTOTIC CELL-DEATH
    BOISE, LH
    GONZALEZGARCIA, M
    POSTEMA, CE
    DING, LY
    LINDSTEN, T
    TURKA, LA
    MAO, XH
    NUNEZ, G
    THOMPSON, CB
    [J]. CELL, 1993, 74 (04) : 597 - 608
  • [4] TREATMENT OF EPISODIC HYPERAMMONEMIA IN CHILDREN WITH INBORN-ERRORS OF UREA SYNTHESIS
    BRUSILOW, SW
    DANNEY, M
    WABER, LJ
    BATSHAW, M
    BURTON, B
    LEVITSKY, L
    ROTH, K
    MCKEETHREN, C
    WARD, J
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1984, 310 (25) : 1630 - 1634
  • [5] Identification of a novel regulatory domain in Bcl-x(L) and Bcl-2
    Chang, BS
    Minn, AJ
    Muchmore, SW
    Fesik, SW
    Thompson, CB
    [J]. EMBO JOURNAL, 1997, 16 (05) : 968 - 977
  • [6] Phase II study of tamoxifen, ifosfamide, epirubicin and cisplatin combination chemotherapy in patients with non-small cell lung cancer failing previous chemotherapy
    Chen, YM
    Perng, RP
    Yang, KY
    Lin, WC
    Wu, HW
    Tsai, CM
    Whang-Peng, J
    [J]. LUNG CANCER, 2000, 29 (02) : 139 - 146
  • [7] DRUG-TARGET INTERACTIONS - ONLY THE 1ST STEP IN THE COMMITMENT TO A PROGRAMMED CELL-DEATH
    DIVE, C
    HICKMAN, JA
    [J]. BRITISH JOURNAL OF CANCER, 1991, 64 (01) : 192 - 196
  • [8] Ealovega MW, 1996, CANCER RES, V56, P1965
  • [9] Ferrandina G, 1997, CANCER RES, V57, P4309
  • [10] Involvement of the CD95 (APO-1/Fas) receptor/ligand system in drug-induced apoptosis in leukemia cells
    Friesen, C
    Herr, I
    Krammer, PH
    Debatin, KM
    [J]. NATURE MEDICINE, 1996, 2 (05) : 574 - 577